AnalystsMatthew KellerMatthew Keller's Stock Forecasts
AnalystsMatthew Keller
Sectors:
Industries:
Analyst Ranking
Bottom 5%
#5095 out of 5342 analysts
Average Return
-31.59%
Win Rate
6%1 out of 16
Risk vs Reward
Poor
Good
Matthew Keller's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Inflarx NvIFRX | +66.67% | $1.02 | $1.70 | 2025-12-30 - 2026-07-31 | Buy |
Matthew Keller Analyst Color
Get additional color on Matthew Keller's coverage of popular stocks
Matthew Keller's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Galectin Therapeutics IncGALT | 3 | Buy | $11.00 | +270.37% | Reiterates | a month ago |
Seres Therapeutics IncMCRB | 1 | Buy | $12.00 | +148.45% | Initiates Coverage On | a month ago |
Inflarx NvIFRX | 3 | Buy | $8.00 | +370.59% | Maintains | 3 months ago |
Phio Pharmaceuticals CorpPHIO | 2 | Buy | $14.00 | +1,265.85% | Reiterates | 6 months ago |
60 Degrees Pharmaceuticals IncSXTP | 2 | Buy | $24.00 | +1,951.28% | Maintains | 6 months ago |
Acurx Pharmaceuticals IncACXP | 2 | Buy | $31.00 | +2,052.78% | Reiterates | 10 months ago |
Kyntra Bio IncKYNB | 2 | Buy | $43.00 | +538.93% | Reiterates | 10 months ago |
Gyre Therapeutics IncGYRE | 1 | Buy | $18.00 | +213.04% | Initiates Coverage On | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.